395074-87-0

Usage

Uses

Used in Pharmaceutical Research:
(1s,3s)-3-(4-nitro-1H-iMidazol-1-yl)cyclobutanaMine is used as a subject of pharmaceutical research for its potential applications in drug development. (1s,3s)-3-(4-nitro-1H-iMidazol-1-yl)cyclobutanaMine's unique structure and functional groups, including the amine and nitro groups, may contribute to its biological activity, warranting further investigation into its therapeutic potential.
Used in Drug Development:
In the field of drug development, (1s,3s)-3-(4-nitro-1H-iMidazol-1-yl)cyclobutanaMine is considered for its possible role in creating new pharmaceutical compounds. (1s,3s)-3-(4-nitro-1H-iMidazol-1-yl)cyclobutanaMine's specific stereochemistry and functional groups could be leveraged to design drugs targeting various medical conditions, pending further research into its pharmacological properties and efficacy.

InChI:InChI=1/C7H10N4O2/c8-5-1-6(2-5)10-3-7(9-4-10)11(12)13/h3-6H,1-2,8H2

Relevant academic research and scientific papers

Synthesis of imidazole intermediates

The invention provides a method for synthesis of compounds of formula wherein R1 and R19 are as defined. Compounds of formula 12 are useful as intermediates for synthesizing compounds having pharmacological activity inhibiting cdk5, cdk2, and GSK-3.

Imidazole derivatives

The invention provides compounds of formula 1 wherein R1, R2, R3, and R4 are as defined, and their pharmaceutically acceptable salts. Compounds of formula 1 are indicated to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating and preventing diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission. Also described are pharmaceutical compositions and methods comprising compounds of formula 1 for treating male fertility and sperm motility; diabetes mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency.